FDA approves Pfizer’s first gene therapy for rare inherited bleeding disorder
The Food and Drug Administration on Friday approved Pfizer’s treatment for a rare genetic bleeding disorder, making it the company’s first-ever gene therapy to win clearance in the U.S.
Pfizer’s First Gene Therapy Gets Approval for Clotting Disorder
Pfizer Inc. won US approval for its first gene therapy, expanding into a promising field of medicine that has proved to be a challenging business.
U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZ™ (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe hemophilia B who currently use factor IX (FIX) prophylaxis therapy,
Pfizer Gets FDA OK For Beqvez Gene Therapy for Hemophilia B
By Colin Kellaher Pfizer has won Food and Drug Administration approval of Beqvez, a one-time gene therapy for certain patients with the inherited
Pfizer Gains as Gene Therapy Wins FDA Nod
The Food and Drug Administration on Friday approved the company’s treatment for a rare genetic bleeding disorder, making it the company’s first-ever gene therapy to win clearance in the U.S.
US FDA approves Pfizer's gene therapy for rare bleeding disorder
The U.S. Food and Drug Administration approved Pfizer's gene therapy for hemophilia B on Friday, the second such therapy for the rare bleeding disorder that typically requires regular infusions of a blood-clotting protein.
US approves gene therapy treatment for hemophilia
Pharmaceutical giant Pfizer has received US approval for a gene therapy against a form of hemophilia, a rare and inherited blood clotting disorder, the company said Friday.Pfizer's genetic therapy targets hemophilia B,
hemophilianewstoday54m
FDA approves Beqvez gene therapy for adults with hemophilia B
Beqvez is indicated for those on preventive treatment with a factor IX replacement therapy or have had life-threatening ...
The American Journal of Managed Care1h
FDA Approves One-Time Gene Therapy Fidanacogene Elaparvovec for Hemophilia B
The FDA has approved fidanacogene elaparvovec-dzkt (Beqvez; Pfizer), a gene therapy administered in a one-time dose, for ...
Sanofi Posts Strong Sales Growth With New Hemophilia Therapy
Sanofi posted first-quarter revenue that exceeded estimates as strong demand for its new hemophilia medicine helped make up ...
US FDA says about 1 in 5 commercial milk samples tested positive for bird flu traces
About one in five samples of commercial milk in the U.S. tested positive for traces of bird flu in a national survey, with a greater proportion coming from areas with infected herds, the U.S. Food and ...
Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point
Centessa Pharmaceuticals plc interim data from the PRESent-2 study, using SerpinPC, is expected to be released in 2024. See ...
BioPharma Dive22h
BioMarin drops drug programs in pipeline cull
The cuts of four pipeline prospects come as BioMarin resets its priorities following the slow launch of its hemophilia gene therapy Roctavian.